Qu – which according to Parsa is the fruit of a collaboration between a global team of experienced AI scientists, ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...

Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...

AstraZeneca's plan to invest £450 million in vaccine R&D in the UK is currently on hold due to ongoing talks with the British ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

AstraZeneca is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The United Kingdom-based global biopharmaceutical company said it ...